Published in Support Care Cancer on September 25, 2010
A scoring system for the prognosis and treatment of malignant bowel obstruction. Surgery (2012) 0.89
[Pharmacological treatment of malignant bowel obstruction in severely ill and dying patients : a systematic literature review]. Schmerz (2012) 0.78
Palliative care in advanced cancer patients: how and when? And where? Oncologist (2012) 0.75
Outcome prognostic factors in inoperable malignant bowel obstruction. Support Care Cancer (2016) 0.75
Successful validation of the palliative prognostic score in terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care. J Pain Symptom Manage (1999) 2.30
Management of malignant bowel obstruction. Eur J Cancer (2008) 1.38
Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer (2001) 1.32
Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer (2000) 1.00
Aggressive pharmacological treatment for reversing malignant bowel obstruction. J Pain Symptom Manage (2004) 0.99
Palliative management of malignant bowel obstruction. Int J Gynecol Cancer (2002) 0.95
Tolerability of continuous subcutaneous octreotide used in combination with other drugs. J Palliat Care (1995) 0.80
Bowel obstruction in home-care cancer patients: 4 years experience. Support Care Cancer (1995) 0.77
The challenge of treating malignant bowel obstruction. J Support Oncol (2006) 0.75
Hiccup in patients with advanced cancer successfully treated with gabapentin: report of three cases. N Z Med J (2003) 1.47
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev (2010) 1.45
Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol (2009) 1.27
Physical exercise and quality of life in breast cancer survivors. Int J Med Sci (2008) 1.14
Palliative sedation in patients with advanced cancer followed at home: a systematic review. J Pain Symptom Manage (2011) 1.06
Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain (2008) 1.04
Weekly administration of paclitaxel: theoretical and clinical basis. Crit Rev Oncol Hematol (2002) 1.01
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival. Clin Cancer Res (2006) 0.93
The Supportive Care Task Force at the University of L'Aquila: 2-years experience. Support Care Cancer (2005) 0.92
Gabapentin in the treatment of hiccups in patients with advanced cancer: a 5-year experience. Clin Neuropharmacol (2010) 0.92
In vivo bone metastases, osteoclastogenic ability, and phenotypic characterization of human breast cancer cells. Bone (2004) 0.91
Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab. Clin Colorectal Cancer (2011) 0.91
Tapentadol in cancer pain management: a prospective open-label study. Curr Med Res Opin (2012) 0.91
Apoptosis induced by oxaliplatin in human colon cancer HCT15 cell line. Anticancer Res (2004) 0.90
The palliative prognostic score and survival in patients with advanced solid tumors receiving chemotherapy. Support Care Cancer (2007) 0.90
"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC Cancer (2010) 0.90
Efficacy and safety of deep, continuous palliative sedation at home: a retrospective, single-institution study. Support Care Cancer (2009) 0.89
Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer. J Cancer Res Clin Oncol (2011) 0.88
Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine. J Pain Symptom Manage (2006) 0.87
Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro. Prostate (2009) 0.87
Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids. Curr Med Res Opin (2013) 0.87
Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. Curr Med Res Opin (2012) 0.86
How do cancer patients receiving palliative care at home die? A descriptive study. J Pain Symptom Manage (2011) 0.86
Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine. J Pain Symptom Manage (2007) 0.86
Low doses of transdermal fentanyl in opioid-naive patients with cancer pain. Curr Med Res Opin (2010) 0.85
Emergencies in patients with advanced cancer followed at home. J Pain Symptom Manage (2012) 0.84
Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx). BMC Med (2013) 0.84
EGFR genomic alterations in cancer: prognostic and predictive values. Front Biosci (Elite Ed) (2011) 0.84
Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer. Clin Cancer Res (2004) 0.84
Opioid switching in patients with advanced cancer followed at home. A retrospective analysis. J Pain Symptom Manage (2012) 0.84
Breakthrough pain in oncology: a longitudinal study. J Pain Symptom Manage (2010) 0.83
Prognostic factors of survival in patients with advanced cancer admitted to home care. J Pain Symptom Manage (2012) 0.83
Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study. Clin Ther (2009) 0.83
Tools for identifying cancer pain of predominantly neuropathic origin and opioid responsiveness in cancer patients. J Pain (2009) 0.82
Acupuncture in the treatment of menopause-related symptoms in women taking tamoxifen. Tumori (2002) 0.82
Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedigrees with identified mutation. Breast Cancer Res Treat (2003) 0.82
Low morphine doses in opioid-naive cancer patients with pain. J Pain Symptom Manage (2006) 0.82
New mutations and protein variants of NBS1 are identified in cancer cell lines. Genes Chromosomes Cancer (2003) 0.81
Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib. Prostate (2011) 0.81
Tapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer pain. Curr Med Res Opin (2014) 0.81
Efficacy of pregabalin in the management of cetuximab-related itch. J Pain Symptom Manage (2006) 0.80
Relationship between background cancer pain, breakthrough pain, and analgesic treatment: a preliminary study for a better interpretation of epidemiological and clinical studies. Curr Med Res Opin (2013) 0.80
Palliative sedation in advanced cancer patients followed at home: a retrospective analysis. J Pain Symptom Manage (2012) 0.80
Knowledge and attitudes of Italian medical oncology residents toward the approach and treatment of pain. J Pain Symptom Manage (2003) 0.79
Efficacy of treatment with tetracyclines to prevent acneiform eruption secondary to cetuximab therapy. Arch Dermatol (2005) 0.79
Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence. Tumori (2015) 0.79
Does pain intensity predict a poor opioid response in cancer patients? Eur J Cancer (2011) 0.79
The effects of low doses of pregabalin on morphine analgesia in advanced cancer patients. Clin J Pain (2013) 0.78
Pain characteristics and analgesic treatment in an aged adult population: a 4-week retrospective analysis of advanced cancer patients followed at home. Drugs Aging (2015) 0.78
Effectiveness and safety of intensive triplet chemotherapy plus bevacizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer patients. Biomed Res Int (2013) 0.78
Epigenetic modulation of PTEN expression during antiandrogenic therapies in human prostate cancer. Int J Oncol (2009) 0.78
Pain intensity as prognostic factor in cancer pain management. Pain Pract (2014) 0.78
The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting. Support Care Cancer (2013) 0.77
Integrating oncology and palliative home care in Italy: the experience of the "L'Aquila per la Vita" Home Care Unit. Tumori (2013) 0.77
Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines. Int J Oncol (2013) 0.77
Her2 crosstalks with TrkA in a subset of prostate cancer cells: rationale for a guided dual treatment. Prostate (2009) 0.77
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer. J Cancer Res Clin Oncol (2013) 0.76
Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype. Int J Oncol (2013) 0.76
Pain evaluation and management: a survey of Italian radiotherapists. Support Care Cancer (2004) 0.75
Palliative care in advanced cancer patients: how and when? And where? Oncologist (2012) 0.75
Topical morphine in the treatment of painful ulcers. J Pain Symptom Manage (2005) 0.75